Expanded Access to Epcoritamab
Sponsor
AbbVie (Industry)
Overall Status
Available
CT.gov ID
NCT05692050
Collaborator
Genmab (Industry)
Study Details
Study Description
Brief Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
Expanded Access to Epcoritamab
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- The participant must not be eligible for an epcoritamab clinical trial.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AbbVie
- Genmab
Investigators
- Study Director: ABBVIE INC., AbbVie
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
AbbVie
ClinicalTrials.gov Identifier:
NCT05692050
Other Study ID Numbers:
- C23-496
First Posted:
Jan 20, 2023
Last Update Posted:
Jan 20, 2023
Last Verified:
Jan 1, 2023
Keywords provided by AbbVie